An observational study in Renal Insufficiency, Chronic, Cardiovascular Diseases and Diagnosis, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-22.
Sponsored by Guangdong Provincial People's Hospital · Observational
The goal of this observational study is to learn about in a total of approximately 2000 patients with cardiovascular disease recruited from about 25 participating sites in China with eGFR\<60 ml/min/1.73 m2 and/or UACR>30 mg/g at least twice 3 months apart within the previous 12 months who had been hospitalized in the cardiology department within the previous 12 months. The main questions it aims to answer are:
Participants will be invited to undergo a baseline visit, and the demographics, lifestyle factors, clinical characteristics, and laboratory tests will be collected.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 149 across 394 observational studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Guangdong Provincial People's Hospital is the lead sponsor of 231 studies on the registry; 101 are open to participants now.
Counted across the registry records on this site, refreshed daily.
a total of approximately 2000 patients with cardiovascular disease recruited from about 25 participating sites in China
Exclusion Criteria:
CKD diagnosis rates
CKD diagnosis rates in overall enrolled patients and subgroups (stratified by isolated estimated glomerular filtration rate (eGFR) measurement, isolated urinary albumin-to-creatinine ratio ( UACR) measurement, and both measurements) will be assessed in 12 month.
Time frame: 1 day
Clinical characteristics
Clinical characteristics in the overall participants and groups stratified by CKD diagnosis (CKD diagnosis, and CKD non-diagnosis) will be reported in 12 months.
Time frame: 1 day
CKD diagnosis/treatment rate
CKD diagnosis/treatment rate in groups stratified by of disease types (HTN, Coronary artery disease (CAD), Heart Failure (HF), type 2 diabetes mellitus (T2DM), etc.) will be assessed in 12 months.
Time frame: 1 day
The number, types, treatment rates of medicine
The number, types, treatment rates of medicine (by class) for renal protection or with potential renal contraindication, awareness in the overall enrolled participants and groups stratified by CKD diagnosis (CKD diagnosis, CKD non-diagnosis) will be reported in 12 months.
Time frame: 1 day
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangdong Provincial People's Hospital